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Definition and prevalence of eosinophilic esophagitis
Eosinophilic  gastrointestinal  diseases  are  increasingly 
recognized and diagnosed disorders that include eosino­
philic esophagitis (EoE), eosinophilic gastroenteritis and 
eosinophilic colitis. Among the eosinophilic gastro  intes­
tinal diseases, EoE has become increasingly prevalent in 
the United States, Switzerland and Australia [1]. Overall, 
EoE  is  a  global  health  condition  now  reported  on  all 
continents  except  Africa,  with  an  incidence  of 
approximately 5 in 10,000 [1,2].
The diagnosis of EoE is based on clinicopathology and 
depends in part on demonstration of esophageal eosino­
philia. A panel of experts proposed consensus recom  men­
dations in 2007 [1], which included the demon  stration of 
15 or more eosinophils in at least one high­powered field 
despite  treatment  with  a  proton  pump  inhibitor  or 
exclusion of gastroesophageal reflux disease (GERD) by 
ambulatory pH monitoring. The clinical presentation of 
EoE  varies  with  age:  infants  and  toddlers  often  have 
difficulty feeding and fail to thrive, school­age children 
present with vomiting and epigastric or chest pain, and 
adolescents and adults present with dysphagia and food 
impaction [3].
EoE  is  considered  a  food­allergy­related  disorder  on 
the  basis  of  several  findings.  Most  patients  are  atopic 
individuals (that is, they have a high rate of food allergen 
sensitization as determined using skin prick and patch 
testing); in addition, EoE patients have a higher rate of 
food anaphylaxis than the general population [4]. More­
over,  nearly  all  EoE  patients  have  complete  remission 
following introduction of an elemental formula diet that 
removes  all  allergens  from  the  diet;  conversely,  the 
disease  flares  on  reintroduction  of  specific  foods  [3]. 
Unlike classic anaphylaxis that typically involves a limited 
set of foods, EoE patients are often sensitized to a myriad 
of  foods,  often  including  food  groups  not  typically 
considered to elicit anaphylaxis [4].
Mechanism of eosinophilic esophagitis
EoE seems to be similar to many other allergic diseases 
with  a  mechanism  of  disease  mediated  by  T  helper  2 
(Th2)  cells.  Experimental  mouse  models  have  demon­
strated key roles for adaptive immunity, Th2 cell cyto­
kines  (especially  interleukin  (IL)­5  and  IL­13)  and 
eosinophilic­attraction chemokines such as CCL26 (also 
called eotaxin­3) in the development of EoE, and also a 
strong  connection  between  allergic  sensitization  and 
inflammation in the respiratory tract and skin [5,6]. IL­13 
has been shown to induce many of the features of EoE in 
human tissue and murine systems, including the induc­
tion of CCL­26 [7]. Genome­wide profiling revealed that 
CCL­26 is overexpressed about 50­fold compared with 
normal controls or patients with GERD [6]. In addition, 
Rothenberg  and  colleagues  [6]  found  that  the  EoE 
transcriptome was consistent across sex, age and familial 
or non­familial inheritance patterns and was independent 
of atopic status, suggesting a common disease mechanism 
despite  phenotypic  variations.  A  potential  proposed 
mechanism  is  that  Th2  cell  activation  leads  to  over­
expression  of  CCL­26  and  thereby  to  migration  of 
eosinophils to the esophagus.
Work  by  Aceves  and  colleagues  [8]  showed  that 
eosinophilic  migration  and  activation  in  EoE  lead  to 
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transforming  growth  factor  β  (TGF­β)  and  its  down­
stream signaling molecule phospho­SMAD2/3 compared 
with  patients  with  GERD  and  healthy  controls.  In 
addition, esophageal biopsies demonstrated an increased 
expression  of  vascular  cell  adhesion  molecule  1 
(VCAM­1)  [8].  This  fibrosis  may  account  for  the 
esophageal  dysmotility  that  leads  to  the  symptoms  of 
dysphagia and food impaction observed in adults. The 
chronic  fibrosis  and  changes  in  inflammatory  markers 
also parallel symptoms observed in asthma.
Genetic links in EoE
The  evidence  indicates  that  EoE  has  a  strong  familial 
association, with nearly 10% of parents of EoE patients 
having a history of esophageal strictures and about 8% 
having  biopsy­proven  EoE  [5].  EoE  also  shows  a  high 
sibling risk ratio (λS) of approximately 80 compared with 
related atopic diseases such as asthma (λS about 2) [9]. 
The first candidate gene for EoE identified was CCL-26, 
the  most  overexpressed  gene  in  the  esophagus  as 
determined  by  genome­wide  expression  profiling  [6]. 
However, the disease­associated allele is present in only 
14% of EoE patients [6].
Rather than looking at the potential pathways, Aceves 
and  colleagues  [10]  examined  response  to  topical 
corticosteroids ­ a standard therapy for the condition ­ in 
patients  with  EoE.  A  positive  response  was  defined  as 
residual eosinophil counts of seven or fewer eosinophils 
per  high­power  field.  Responders  had  a  reduced 
esophageal  remodeling  with  decreased  fibrosis,  fewer 
TGF­β­  and  pSmad2/3­positive  cells  and  decreased 
vascular  activation  following  therapy  with  the  cortico­
steroid budesonide. Responders were more likely to have 
a  CC  genotype  at  the  ­509  position  in  the  TGF­β 
promoter than were non­responders.
More recently, a multi­center genome­wide association 
study (GWAS) has identified the thymic stromal lympho­
poietin (TSLP) gene, at 5q22, as an important candidate 
gene in the pathogenesis of the disease [11]. TSLP is an 
epithelial­derived  cytokine  that  activates  professional 
antigen­presenting  cells,  such  as  dendritic  cells,  which 
initiate Th2­type allergic responses [12]. The same study 
also  found  an  increased  expression  of  TSLP  in  the 
esophagi  of  patients  with  EoE  compared  with  healthy 
controls [11].
The most recent finding by Sherrill et al. [13] adds to 
our understanding of the interaction of TSLP and EoE. 
This genomic analysis [13] focused on key allergic single 
nucleotide polymorphisms (SNPs) along with epithelial 
SNPs and compared them in atopic and healthy controls. 
In  addition  to  replicating  the  significant  association 
between SNPs at TSLP and EoE, they found that TSLP 
variants remained significant when compared with atopic 
controls in their study [13] or asthma controls from the 
previous GWAS analysis [11]. However, variations in the 
TSLP  gene  were  not  significant  when  compared  with 
controls,  probably  because  of  the  small  number  of 
controls used. TSLP has also been found to be associated 
with  atopic  dermatitis  [14]  and  asthma  [15]  compared 
with  healthy  controls.  The  finding  of  TSLP  being 
significant only among the atopic controls could be due 
either  to  the  other  studies  not  removing  patients  with 
EoE (which is commonly atopic) from their control group 
or  to  the  possibility  that  TSLP  might  trigger  multiple 
atopic diseases depending on secondary signals.
Sherrill and colleagues [13] also found a SNP in the 
TSLP  receptor  (TSLPR)  gene  that  was  associated  with 
EoE. The gene encoding the TSLP receptor is located on 
the pseudoautosomal region on Xp22.3 and Yp11.3 and it 
was  significantly  associated  with  disease  only  in  male 
patients  with  EoE.  Given  that  EoE  is  more  common 
among males by a 2:1 ratio [1], the finding of a SNP in the 
TSLPR  suggests  a  potential  mechanism  for  the  male 
dominance observed in EoE. Sherrill et al. [13] also noted 
one  additional  finding  that  may  suggest  alternative 
pathways for the treatment or the pathogenesis of EoE: 
they  observed  that  stimulation  of  primary  esophageal 
epithelial  cells  with  poly  I:C  (a  double­stranded  RNA 
mimetic) induced the expression of TSLP mRNA. This 
induction was dependent on Toll­like receptor (TLR)­3 
stimulation.  TLR­3  recognizes  double­stranded  RNA, 
which is found in some viruses such as reoviruses. These 
results suggest a second hit for the development of EoE 
with a viral trigger and allergen exposure. In the lung and 
skin  TSLP  is  produced  primarily  by  epithelial  cells  in 
response  to  Th2  cytokines  or  TLR3  agonists,  and  it 
subsequently  targets  dendritic  cells  to  secrete  Th2­
inducing activity, including Th2 cytokine and chemokine 
production.
These findings [13] suggest a unique potential mecha­
nism  for  the  induction  of  EoE.  Could  food  allergens 
trigger the TLR­3 receptor, inducing TSLP and causing 
the activation of the Th2 pathway, leading to eosinophilic 
inflammation in the esophagus? Or is there a ‘second hit’, 
a virus that makes susceptible people develop EoE?
Potential pathways for treatment
The  current  treatment  options  for  EoE  involve  the 
avoidance of the trigger (foods) and the treatment of the 
underlying inflammation with topical corticosteroids [1]. 
Treatment with food avoidance is highly successful, with 
rates  close  to  100%  with  elemental  diets  (amino  acid 
formulas) [1]. However, these formulas are unpalatable 
and lead to low quality of life. Eliminating foods on the 
basis of allergy testing or empirical elimination leads to 
resolution  of  esophageal  eosinophilia  in  50  to  80%  of 
patients, depending on the diet and the age of the patient 
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[3]. These diets are also difficult to maintain and many 
patients refuse to continue them. Treatment with topical 
steroids can work for 50 to 80% of patients, but there are 
also some drawbacks. Topical corticosteroids can lead to 
localized yeast infections and have potential long­term 
side effects, including growth suppression and osteopenia 
(low bone density); however, these have not been studied 
or seen in short­term studies. Other treatments currently 
being  investigated  include  anti­immunoglobulin  (Ig)E, 
anti­IL­5,  anti­IL­13  and  chemoattractant  homologous 
receptor expressed on Th2 cells (CRTH2) antagonist or 
topical corticosteroids [16­18].
The recent identification of TSLP and its receptor as 
key components in the EoE pathogenesis [13] suggests 
that  blockage  of  the  TSLP­TSLP  receptor  activation 
could provide an attractive approach to treating the cause 
of EoE. In addition, the new finding that TLR­3 induces 
TSLP suggests that a second hit (a virus) may trigger this 
pathway. If a particular virus or microorganism unique 
for EoE were identified, this would allow the development 
of a preventive strategy. This is unlikely to occur in the 
near  future,  but  treatment  with  TLR­3  antagonists  or 
blocking  downstream  signaling  already  represent  hope 
for the treatment of EoE.
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